PMID- 32801749 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 13 DP - 2020 TI - Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases. PG - 7189-7197 LID - 10.2147/OTT.S262039 [doi] AB - Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is a specific subtype of peripheral T cell lymphoma (PTCL) with a poor prognosis. To date, there exist no standard therapeutic regimens for relapsed/refractory (R/R) ENKTL. More potent treatment strategies are urgently needed to improve the survival of these patients with R/R ENKTL. Herein, we present three R/R ENKTL patients who failed prior therapies (L-asparaginase containing chemotherapy, radiotherapy or biological-cell therapy, etc.) benefited from the combination regimen comprised of anti-programmed-death-1 (PD-1) antibody toripalimab, chidamide, etoposide, and thalidomide. They received the treatment regimen continuously until the disease progression occurs. As of data collection, two patients achieved complete remission (CR) after 4, 6 cycles of treatment, respectively, and another patient was evaluated as partial remission (PR) after 2 cycles. Treatment-related adverse events (AEs) mainly presented grade 2~3 leukocytopenia and anemia, which were controllable. It follows that PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) regimen may be a promising choice for patients with R/R ENKTL and warrants further investigation. CI - (c) 2020 Du et al. FAU - Du, Lijun AU - Du L AUID- ORCID: 0000-0002-4265-944X AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Zhang, Lei AU - Zhang L AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Li, Ling AU - Li L AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Li, Xin AU - Li X AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Yan, Jiaqin AU - Yan J AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Wang, Xinhua AU - Wang X AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Fu, Xiaorui AU - Fu X AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Sun, Zhenchang AU - Sun Z AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Zhang, Xudong AU - Zhang X AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Li, Zhaoming AU - Li Z AUID- ORCID: 0000-0002-2876-5182 AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Wu, Jingjing AU - Wu J AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Yu, Hui AU - Yu H AUID- ORCID: 0000-0002-5287-9155 AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Chang, Yu AU - Chang Y AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Zhou, Zhiyuan AU - Zhou Z AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Nan, Feifei AU - Nan F AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Wu, Xiaolong AU - Wu X AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Tian, Li AU - Tian L AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. FAU - Zhang, Mingzhi AU - Zhang M AUID- ORCID: 0000-0001-8428-6090 AD - Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People's Republic of China. LA - eng PT - Case Reports DEP - 20200727 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC7394590 OTO - NOTNLM OT - NK/T-cell lymphoma OT - PD-1 OT - chidamide OT - relapsed/refractory OT - targeted treatment COIS- The authors report no conflicts of interest in this work. EDAT- 2020/08/18 06:00 MHDA- 2020/08/18 06:01 PMCR- 2020/07/27 CRDT- 2020/08/18 06:00 PHST- 2020/05/14 00:00 [received] PHST- 2020/07/06 00:00 [accepted] PHST- 2020/08/18 06:00 [entrez] PHST- 2020/08/18 06:00 [pubmed] PHST- 2020/08/18 06:01 [medline] PHST- 2020/07/27 00:00 [pmc-release] AID - 262039 [pii] AID - 10.2147/OTT.S262039 [doi] PST - epublish SO - Onco Targets Ther. 2020 Jul 27;13:7189-7197. doi: 10.2147/OTT.S262039. eCollection 2020.